Wide Ranks

COYA

Coya Therapeutics, Inc.

6.65

Top Statistics
Market Cap 111 M Forward PE -5.32 Revenue Growth 0.00 %
Current Ratio 15.31 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -111.98 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -7.21 Enterprise / Revenue 8.38 Price To Sales Trailing12 Months 11.63
Profitability
Profit Margins -111.98 % Operating Margins -116.56 %
Balance Sheet
Total Cash 31 M Total Cash Per Share 1.86 Total Debt
Total Debt To Equity Current Ratio 15.31 Book Value Per Share 2.10
All Measures
Short Ratio 127.00 % Message Board Id finmb_700238507 Shares Short Prior Month 186085
Return On Equity -0.5083 City Houston Uuid 36f97ab5-2cb2-316d-aa68-d031cf853924
Previous Close 6.38 First Trade Date Epoch Utc 1 B Book Value 2.10
Volume 71725 Price To Book 3.16 Fifty Two Week Low 4.75
Total Cash Per Share 1.86 Total Revenue 9 M Shares Short Previous Month Date 1 B
Target Median Price 15.25 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -116.56 % Target Mean Price 15.62 Net Income To Common -10699036
Short Percent Of Float 0.0116 Implied Shares Outstanding 16 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 71370 Average Volume10days 71370
Total Cash 31 M Next Fiscal Year End 1 B Revenue Per Share 0.6870
Held Percent Insiders 0.0703 Ebitda Margins -116.27 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 6.38
Target Low Price 14.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.15
Open 6.44 Free Cashflow -8040114 State TX
Dividend Yield 0.00 % Return On Assets -0.2934 Time Zone Short Name EST
Trailing Eps -0.6500 Day Low 6.43 Address1 5850 San Felipe Street
Shares Outstanding 16 M Price Hint 2 Target High Price 18.00
Website https://www.coyatherapeutics.com 52 Week Change 0.2477 Average Volume 79475
Forward Eps -1.25 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 1339.20 % Is_sp_500 False Regular Market Day High 6.78
Profit Margins -111.98 % Fifty Two Week High 10.69 Day High 6.78
Shares Short 180996 Regular Market Open 6.44 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 8.38 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0108 Operating Cashflow -10120135 Currency USD
Time Zone Full Name America/New_York Market Cap 111 M Is_nasdaq_100 False
Zip 77057 Quote Type EQUITY Industry Biotechnology
Long Name Coya Therapeutics, Inc. Regular Market Day Low 6.43 Held Percent Institutions 0.1997
Current Price 6.65 Address2 Suite 500 Enterprise To Ebitda -7.21
Financial Currency USD Current Ratio 15.31 Gross Margins -20.76 %
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 14 M Two Hundred Day Average 7.52 Enterprise Value 80 M
Price To Sales Trailing12 Months 11.63 Forward PE -5.32 Regular Market Volume 71725
Ebitda -11108714 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).

The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.

The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.

It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage.

The company has a collaboration with Dr.

Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis.

The company was incorporated in 2020 and is headquartered in Houston, Texas.